首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   428篇
  免费   13篇
  国内免费   3篇
耳鼻咽喉   10篇
儿科学   3篇
妇产科学   47篇
基础医学   56篇
口腔科学   2篇
临床医学   21篇
内科学   60篇
皮肤病学   7篇
神经病学   35篇
特种医学   16篇
外科学   89篇
综合类   1篇
预防医学   17篇
眼科学   3篇
药学   10篇
肿瘤学   67篇
  2023年   2篇
  2022年   5篇
  2021年   8篇
  2020年   7篇
  2019年   11篇
  2018年   12篇
  2017年   3篇
  2016年   5篇
  2015年   5篇
  2014年   14篇
  2013年   27篇
  2012年   18篇
  2011年   40篇
  2010年   24篇
  2009年   12篇
  2008年   30篇
  2007年   28篇
  2006年   33篇
  2005年   21篇
  2004年   27篇
  2003年   20篇
  2002年   23篇
  2001年   20篇
  2000年   12篇
  1999年   5篇
  1998年   7篇
  1997年   4篇
  1995年   3篇
  1994年   2篇
  1993年   2篇
  1992年   3篇
  1990年   3篇
  1989年   3篇
  1987年   2篇
  1985年   1篇
  1984年   1篇
  1981年   1篇
排序方式: 共有444条查询结果,搜索用时 343 毫秒
441.
Immunohistochemical evaluation of lung carcinomas for key enzymes involved in cellular metabolism (lactate dehydrogenase LDH 1 and 5, pyruvate dehydrogenase PDH, pyruvate dehydrogenase kinase PDHK-1, monocarboxylate transporters MCT 1, 2 and 4, glucose transporter GLUT1, hypoxia inducible factors HIF1alpha and 2alpha) show a complementary metabolic profile between cancer cells and tumor-associated stroma. Cancer cells share enzyme/transporter activities suggestive of an anaerobic metabolism with high affinity for glucose absorption, anaerobic glycolysis and lactate extrusion. On the other hand, the tumour-associated fibroblasts express patterns involved in aerobic pathways and lactate oxidation. These findings bring forward the hypothesis that tumor associated stroma is an accomplice in tumor growth and survival sustaining an independent cellular and metabolic tumor domain. The development of agents exploiting such cancer specific metabolic pathways may prove of importance in the treatment of lung cancer.  相似文献   
442.

Background

Although colorectal cancer (CRC) is a disease of the older patients, older patients are under-represented from randomized trials. Herein we conducted a retrospective analysis for the effect of panitumumab in the management of older patients (≥65?years) patients with metastatic CRC (mCRC) in the Hellenic Oncology Research Group's (HORG) database.

Methods

Τhe efficacy of panitumumab-based chemotherapy as front-line treatment in older patients with mCRC was assessed.

Results

In total, 110 older patients with KRAS exon 2 wild type tumors were treated with chemotherapy plus panitumumab. The median age was 74?years; 69.9% of the patients were male, with left-sided primary tumors (78.2%), ECOG Performance Status 0–1 (95.4%) and median number of metastatic sites 2. Sixty-two (Overall Response Rate-ORR: 56.4%; 95% CI: 48.8%–68.1%) achieved an objective response, while 21 (19.1%) had stable disease. Median Progression free survival (PFS) was 9.4?months (95% CI: 7.8–11.0?months) and median Overall survival (OS) 23.0?months (95% CI: 20.6–25.3?months). Additionally, a statistically significant difference in ORR (62.7% vs. 33.3%; p?=?.014), median PFS (12.9 vs. 5.7?months; p?=?.001) and median OS (31.6 vs. 16.7?months; p?<?.001) was observed in patients with left-sided compared to right-sided primary tumor. There was no treatment-related death. Grade 3–4 toxicities were neutropenia (8.9%) and diarrhea (14.5%) whereas skin rash grade 2 or 3 was recorded in 41.1% and 10.7%, respectively.

Conclusions

The results of this retrospective study provide the evidence that combination chemotherapy plus panitumumab is active and well tolerated in older patients with mCRC.  相似文献   
443.

Background and purpose

Lifestyle factors have been implicated in the long-lasting neurodegenerative process in prodromal Parkinson's disease (pPD). The aim was to investigate the associations between adherence to a Mediterranean diet (MeDi) and longitudinal changes of pPD probability and the development of Parkinson's disease (PD) or pPD in a Mediterranean older population.

Methods

Data from the Hellenic Longitudinal Investigation of Aging and Diet cohort (community-dwelling individuals, aged ≥ 65 years) were used. A detailed food frequency questionnaire was used to evaluate dietary intake and calculate MeDi adherence score, ranging from 0 to 55, with higher scores indicating higher adherence. The probability of pPD was calculated according to the updated Movement Disorder Society research criteria.

Results

In all, 1047 non-PD/dementia with Lewy bodies (DLB) participants were followed for 3 ± 1 years. MeDi adherence was associated with lower increase in pPD probability over time (b = −0.003, 95% confidence interval −0.006 to −0.001, p = 0.010). Forty-nine participants had incident possible/probable pPD (i.e., pPD probability ≥ 30%). Compared to the participants in the lowest quartile of MeDi adherence, those in the higher quartiles had an approximately 60%–70% lower risk for possible/probable pPD (p for trend 0.003). MeDi–pPD associations were driven by both motor and non-motor pPD markers and not from risk markers. Also, 21 participants were diagnosed with PD/DLB at follow-up. For each unit increase in the MeDi score, there was a 9%–10% lower risk for PD/DLB (hazard ratio 0.906 [95% confidence interval 0.823–0.997], p = 0.044).

Conclusions

Mediterranean diet adherence is associated with lower increase in pPD probability over time and lower possible/probable pPD and PD/DLB incidence in older Mediterranean people. More studies are needed to confirm our results in other populations.  相似文献   
444.
Journal of Neurology - To examine whether associations between individual neuropsychiatric symptoms (NPS) and incident Alzheimer’s dementia (AD) differ in men versus women. Data were acquired...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号